HPB Surgery › Neuroendocrine Tumours
Neuroendocrine Tumours
Surgical management of pancreatic and GI neuroendocrine tumours (NETs), following national COSA guidelines authored by Dr. Nahm.
Overview
Neuroendocrine Tumours (NETs)
Neuroendocrine tumours (NETs) are a diverse group of tumours that arise from neuroendocrine cells throughout the body. They most commonly occur in the gastrointestinal tract and pancreas. NETs vary widely in behaviour — from slow-growing, low-grade tumours to aggressive, high-grade cancers. Surgical resection remains the cornerstone of treatment for localised NETs.
National Guidelines Author
Dr. Nahm is the author of the national COSA (Clinical Oncology Society of Australia) guidelines for the surgical management of neuroendocrine tumours, reflecting his expertise and leadership in this subspecialty.
Types of NETs
Pancreatic NETs (pNETs)
Include insulinoma, gastrinoma, glucagonoma and non-functional pNETs. Surgical resection is recommended for most.
Small Bowel NETs (Carcinoids)
The most common GI NET. Often present with carcinoid syndrome. Surgical resection of the primary tumour and lymph nodes is recommended.
Appendiceal NETs
Usually found incidentally at appendicectomy. Small tumours require no further surgery; larger tumours may require right hemicolectomy.
Rectal NETs
Small rectal NETs can be managed endoscopically; larger tumours require surgical resection.
Liver Metastases from NETs
Liver resection for NET liver metastases can provide excellent palliation and, in selected cases, cure.
Multidisciplinary Management
NETs are managed through a multidisciplinary approach involving surgeons, oncologists, nuclear medicine physicians and endocrinologists. Dr. Nahm participates in dedicated NET MDT meetings and applies the latest evidence-based guidelines — including those he himself authored — to provide optimal individualised care.